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Self-renewal of human embryonic stem cells (ESCs)
is promoted by FGF and TGFb/Activin signaling,
and differentiation is promoted by BMP signaling,
but how these signals regulate genes critical to the
maintenance of pluripotency has been unclear. Using
a definedmedium, we show here that both TGFb and
FGF signals synergize to inhibit BMP signaling; sus-
tain expression of pluripotency-associated genes
such as NANOG, OCT4, and SOX2; and promote
long-term undifferentiated proliferation of human
ESCs. We also show that both TGFb- and BMP-
responsive SMADs can bind with the NANOG proxi-
mal promoter.NANOG promoter activity is enhanced
by TGFb/Activin and FGF signaling and is decreased
by BMP signaling. Mutation of putative SMAD bind-
ing elements reduces NANOG promoter activity to
basal levels and makes NANOG unresponsive to
BMP and TGFb signaling. These results suggest
that direct binding of TGFb/Activin-responsive
SMADs to the NANOG promoter plays an essential
role in sustaining human ESC self-renewal.
INTRODUCTION
Although the signaling pathways that contribute to the sustained
undifferentiated proliferation of human embryonic stem cells
(ESCs) remain to be completely elucidated, it is clear that several
developmentally important signals are involved. Among them,
fibroblast growth factor (FGF) family members and transforming
growth factor b (TGFb)/Activin promote self-renewal (Amit et al.,
2004; Beattie et al., 2005; Besser, 2004; Greber et al., 2007;
James et al., 2005; Levenstein et al., 2005; Li et al., 2005; Lu
et al., 2006; Ludwig et al., 2006b; Sato et al., 2004; Vallier
et al., 2005; Wang et al., 2005; Xiao et al., 2006; Xu et al.,
2005a, 2005b; Yao et al., 2006), and bone morphogenetic
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et al., 2002, 2005b). Clonal growth of human ESCs is supported
by basic FGF (bFGF) on fibroblasts in the presence of a commer-
cially available serum substitute (Amit et al., 2000), and the same
medium supports human ESCs in the absence of direct contact
with feeder layers if it is conditioned on fibroblasts prior to use
(Xu et al., 2001). Higher concentrations of bFGF support human
ESCs in the absence of fibroblasts or fibroblast-conditioned
medium, and these higher concentrations are, in part, needed
because of the instability of bFGF in those conditions (Levenstein
et al., 2005). These initial studies were performed in medium in-
cluding a commercially available, poorly defined serum replace-
ment that contains BMP activity at sufficient levels to induce
differentiation of human ESCs in the absence of fibroblasts (Xu
et al., 2005b). Under these conditions, inhibition of BMP activity
is beneficial to human ESC self-renewal, and at high concentra-
tions, bFGF itself has an ability to inhibit BMP signaling (Xu et al.,
2005b). However, inhibition of BMP activity by itself is not suffi-
cient for the long-term maintenance of human ESCs, indicating
additional roles of FGF signaling (Xu et al., 2005b).
Undifferentiated human ESCs are characterized by activation
of SMAD2/3 (TGFb/Activin pathway) and repression of SMAD1/
5/8 (BMP pathway) (Beattie et al., 2005; Besser, 2004; Greber
et al., 2007; James et al., 2005; Vallier et al., 2005; Xiao et al.,
2006; Xu et al., 2005b). The TGFb superfamily of secreted factors
includes TGFb, Activins, Nodal, and BMPs, several of which are
expressed by human ESCs (Beattie et al., 2005; Besser, 2004;
Greber et al., 2007; James et al., 2005; Sperger et al., 2003;
Vallier et al., 2005; Xiao et al., 2006; Xu et al., 2005b). TGFb
superfamily members signal by bringing together type I and
type II receptors on the cell surface. The type II receptor phos-
phorylates the type I receptor, which then propagates the signal
by phosphorylating receptor-activated SMAD (R-SMAD) pro-
teins (Shi and Massague, 2003). TGFb/Activin signaling occurs
through SMAD2/3, and BMP signaling occurs through SMAD1/
5/8. Both groups of R-SMADs, once activated, bind the same
co-SMAD (SMAD4), and the resulting complex assembles with
other transcriptional factors in the nucleus, which then regulate
specific gene expression. Receptors for Activin (Act-IB/ALK4
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expressed by human ESCs (Sperger et al., 2003). Human
ESCs treated with TGFb/Activin inhibitor SB431542 rapidly dif-
ferentiate when cultured on fibroblasts or in fibroblast-condi-
tioned medium (Beattie et al., 2005; James et al., 2005; Vallier
et al., 2005). At low or modest concentrations of FGFs, both
Activin and TGFb have strong positive effects on undifferentiated
proliferation of human ESCs, and based on the SB431542 inhib-
itor studies, it has been suggested that TGFb/Activin signaling is
essential for human ESC self-renewal. However, when TGFb/Ac-
tivin signaling is inhibited with SB431542, there is a concomitant
rise in BMP signaling activity, evidenced by an increased phos-
phorylation of SMAD1/5/8 (Beattie et al., 2005; James et al.,
2005; Vallier et al., 2005), so it has been somewhat unclear
whether signaling through SMAD2/3 is merely acting to inhibit
the sister BMP pathway or whether TGFb/Activin signaling has
other independent roles.
Recent studies have revealed transcriptional interaction
between FGF, TGFb, and BMP pathways in human ESCs. For
example, Activin induces bFGF expression, and bFGF induces
Tgfb1/TGFb1 andGrem1/GREM1 (a BMP antagonist) expression
and inhibitsBmp4/BMP4 expression in bothmouse embryonic fi-
broblast (feeder cells for human ESCs) and human ESCs (Greber
et al., 2007). This reciprocity of induction between the FGF and
TGFb/Activin pathways may explain why at high doses of bFGF,
exogenous TGFb has very modest effects on undifferentiated hu-
manESCproliferation in defined conditions (Ludwig et al., 2006b),
and, similarly, at sufficient doses of Activin, the beneficial dose of
exogenous FGF is greatly reduced (Vallier et al., 2005; Xiao et al.,
2006). Taken together, these studies raise thequestion ofwhether
both FGF and TGFb/Activin signals are required or whether either
alone is sufficient to sustain human ESC self-renewal.
How the extrinsic factors that sustain human ESCs intersect
with the intrinsic transcriptional networksessential topluripotency
remains largely unexplored. The core transcription factors essen-
tial to maintaining both mouse and human ESCs include the ho-
meodomain transcription factors NANOG and OCT4 (POU5F1)
and the HMG-box transcription factor SOX2 (Chambers et al.,
2003; Hay et al., 2004; Matin et al., 2004; Mitsui et al., 2003; Nich-
ols et al., 1998; Zaehres et al., 2005). Disruption ofOct4 orNanog
leads to mouse ESC differentiation to trophectoderm and extra-
embryonic endoderm, respectively (Chambers et al., 2003;Mitsui
et al., 2003; Nichols et al., 1998). Inhibition of NANOG gene ex-
pression also causes human ESC differentiation to extraembry-
onic cell lineages (Hyslop et al., 2005; Zaehres et al., 2005), and
overexpression allows feeder-independent proliferationof human
ESCs (Darr et al., 2006). NANOG, OCT4, and SOX2 co-occupy
and regulate many developmentally important homeodomain
genes and collaborate to forman extensive regulatory circuitry in-
cluding autoregulatory and feedforward loops (Boyer et al., 2005;
Kuroda et al., 2005; Lee et al., 2006; Rodda et al., 2005).
Here, we further dissect the requirements of FGF and TGFb/
Activin signaling in human ESC self-renewal and explore the links
between extrinsic TGFb/Activin signaling and the intrinsic tran-
scriptional regulators of human ESC self-renewal and pluripo-
tency. We find that neither FGF nor TGFb signaling alone can
sustain the long-term undifferentiated proliferation of human
ESCs in our specific culture conditions. We also find that SMADs
bind with the NANOG promoter and that SMAD2/3 activityenhances NANOG promoter activity. These results establish a
direct link between an extrinsic factor that maintains human
ESC self-renewal and the transcriptional regulation of this key
pluripotency gene NANOG.
RESULTS
Both FGF and TGFb Signals Are Required to Sustain
Human ESC Self-Renewal
For these studies, we used a definedmedium TeSR1 (T1) that in-
cludes bFGF andTGFb1 (Ludwig et al., 2006b). Using a luciferase
reporter assay (Lopez-Rovira et al., 2002) that we have previ-
ously shown responds to BMP activity in human ESCs in
a dose-dependent manner (Xu et al., 2005b), FGF and TGFb
signaling synergistically repressed BMP signaling in H9 human
ESCs (Figures 1A and S1 available online). We have previously
shown that BMP4-treated human ESCs differentiate to tropho-
blast in conditioned medium and that human chorionic gonado-
trophin (HCG) is dramatically upregulated during this differentia-
tion (Xu et al., 2002). The antagonism between FGF and BMP
signaling in human ESCs cultured in T1 was also apparent in
a dose-dependent inhibition of HCG secretion by bFGF in
BMP4-treated human ESCs (Figure 1B).
The antagonism between FGF or TGFb signaling and BMP sig-
naling was analyzed in human ESCs cultured in T1 medium by
using an inhibitor of FGF signaling, SU5402, and an inhibitor of
TGFb signaling, SB431542 (SB) (Figure S2). SU5402 alone or to-
gether with BMP4 reduced the level of phosphorylated SMAD2/
3, and SU5402 also enhanced BMP4 expression. SB431542
synergized with BMP4 to elevate the level of phosphorylated
SMAD1/5/8 and BMP4 production. These data indicate that
FGF and TGFb signaling antagonize BMP signaling either di-
rectly by repressing SMAD1/5/8 phosphorylation or BMP4 pro-
duction or indirectly by promoting SMAD2/3 phosphorylation.
We next tested the long-term requirements of FGF and TGFb
signaling for human ESC self-renewal by culturing H1 cells in T1
medium without bFGF (T1[]bFGF) or with 10 mM SB (T1[+]SB).
After 7 days of culture, almost all of the cells cultured in
T1()bFGF remained OCT4+, about half of the cells in T1(+)SB
remained OCT4+, and almost all of the cells in T1()bFGF(+)SB
became OCT4 (Figures S3 and 2A). Continuous treatment of
the cells for 14 days (cells split at 7 days) led to a further decline
in the OCT4+ percentage in each of the treatment groups
(62.9%, 12.2%, and 3.9% for T1[]bFGF, T1[+]SB, and
T1[]bFGF[+]SB, respectively). Cell numbers in T1(+)SB re-
mained similar to that of T1 control but were greatly reduced in
T1[]bFGF (Figure 2A). Similar results were obtained from H9
cells (data not shown). These data suggest that both FGF and
TGFb signaling are required to maintain long-term human ESC
self-renewal in T1 and that FGF signaling also sustains cell pro-
liferation independent of TGFb signaling. Microarray gene ex-
pression profiles (Table S1), QPCR (Figure 2B), andwestern blot-
ting (Figure S4) of human ESCs subjected to inhibition of FGF
and TGFb signaling paralleled these results, i.e., inhibition of
either FGF or TGFb signaling alone led to a modest initial decline
in the expression levels of pluripotency-associated genes such
as OCT4, NANOG, and NODAL, and inhibition of both signals
led to dramatic, rapid decline in expression of these genes.
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Among the key transcription factors known to control pluripo-
tency, NANOG expression was repressed the most by inhibition
of TGFb signaling, either in the presence or absence of bFGF
(Table S1 and Figure 2B). Therefore, we decided to examine
whether NANOG itself is a direct target of SMAD-mediated sig-
naling pathways. Both TGFb- and BMP-responsive SMADs bind
to DNA via their MAD homolog 1 (MH1) domain (Kim et al., 1997;
Shi et al., 1998), and SMAD binding elements (SBEs) have been
identified in genes responsive to TGFb and BMP signaling, in-
cluding a consensus sequence (G)AGAC and its complement
GTCT(C) (Massague and Wotton, 2000). Regulatory elements
essential forNANOG expression in human ESCs have previously
been mapped to an upstream 404 bp proximate promoter region
(Kuroda et al., 2005). We noticed that this region also contains
four putative SBEs surrounding the Octamer/Sox elements
(Figures 3A and S5).
Figure 1. Either FGF or TGFb Signaling An-
tagonizes BMP Signaling
(A) Both FGF and TGFb signals synergistically re-
press BMP signal in human ESCs in luciferase re-
porter assays. H9 cells were transfected with
pID120-Lucanda traceamount of pRL-tk (for inter-
nal control) onday1. Treatments of the cells started
on day 2 with T1 medium (T1) or T1 ± 100 ng/ml
bFGF, 0.6 ng/ml TGFb1, 10 mMSU5402 (SU, inhib-
itor of FGF receptors), and 10 mM SB431542 (SB,
inhibitor of TGFb receptors). The cells were lysed
on day 3 for analysis of luciferase activity.
(B) bFGF inhibits HCG secretion from trophoblast
differentiated from BMP4-treated human ESCs.
H14 cells cultured in fibroblast-conditioned me-
dium (CM) were rinsed with DMEM/F12 basal me-
dium and switched to CM or T1 medium with or
without various concentrations of bFGF (F) and
100 ng/ml BMP4 (B4) for 7 days with daily refresh-
ment of the media. The spent media were col-
lected on day 7 and assayed for HCG. Results
are shown as mean ± standard deviation. *p <
0.01 compared to T1()bFGF(+)BMP4. SB has
previously been shown to inhibit the levels of
phosphorylated SMAD2 and SMAD3 in human
ESCs (James et al., 2005).
By using chromatin immunoprecipita-
tion (ChIP) and quantitative polymerase
chain reaction (QPCR), we analyzed en-
richment of the NANOG promoter region
from the nuclear lysates of H1 cells with
anti-SMAD1/5/8 or anti-SMAD2/3 anti-
bodies (Figure 3B). Enrichment of the
promoter region by anti-SMAD2/3 anti-
body was high for control human ESCs
cultured in T1 but reduced dramatically
for SB431542-treated cells and reduced
modestly (but significantly) for BMP4-
treated cells. In contrast, enrichment of
the promoter region by anti-SMAD1/5/8
antibody was low for control human
ESCs, was increased markedly for
BMP4-treated cells, and was increased modestly (but signifi-
cantly) for SB431542-treated cells. These results suggest that
both BMP-responsive SMADs (SMAD1, -5, and -8) and TGFb-re-
sponsive SMADs (SMAD2 and -3) can interact with the NANOG
proximal promoter. The binding by SMAD2/3 is dominant in un-
differentiated human ESCs and is sustained by TGFb signaling,
whereas the binding by SMAD1/5/8 is low in human ESCs but in-
creases with BMP signaling.
Electrophoretic mobility shift assays (EMSA) were performed
with biotin-labeled 80 bp DNA amplified from the proximal
NANOG promoter region, which contained the four putative
SBEs surrounding the Octamer/Sox elements (Figures 3A and
S5). This probe allowed us to pull down SMAD2/3 from human
ESCs, as verified by western blotting (Figure 4A). By using this
probe, we observed a clear shift after incubation with the nuclear
extract of H9 cells and a supershift when an antibody against
SMAD2/3, but not SMAD1/5/8, was present in the incubation
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were mutated in the probe (Figure 4B). The shift and supershift
were also present with another human ESC line H1 but absent
with IMR90 fetal fibroblasts (data not shown), suggesting that
the SMAD binding occurs in human ESCs, but not the fibro-
blasts. H9 cells treated with BMP4 for 3 hr caused a supershift
with the anti-SMAD1/5/8 antibody, and the supershift with the
anti-SMAD2/3 antibody remained; on the other hand, only
a supershift with the anti-SMAD1/5/8 antibody occurred on H9
Figure 2. FGF and TGFb Synergize to
Sustain Human ESC Self-Renewal
(A) bFGF and TGFb effects on H1 cell growth and
maintenance of OCT4 expression. 3.5 3 105 H1
cells were seeded in individual wells of 6-well
plates in triplicate and cultured in T1 medium,
T1 + 10 mM SB431542 (T1[+]SB), T1  100 ng/ml
bFGF (T1[]bFGF), or T1  100 ng/ml bFGF +
10 mM SB (T1[]bFGF[+]SB). The cells were split
1:3 on day 7 into the correspondingmedia and cul-
tured for an additional 7 days. Total cell number
per group was counted on days 3 and 7 of each
passage (labeled as p1d3, p1d7, p2d3, and
p2d7, respectively), and OCT4+ cell percentage
was determined by flow cytometry on p1d7 and
p2d7. Results are shown as mean ± standard
deviation. *p < 0.01 compared to T1.
(B) Expressionofpluripotencygenes inhumanESCs
treated with various growth factors or inhibitors. H9
cells were cultured in T1, T1()bFGF, T1(+)SB, or
T1()bFGF(+) SBmedium for 1, 3, or 5 days and fol-
lowed by QPCR for expression of POU5F1 (OCT4)
and NANOG. *p < 0.05, **p < 0.01 compared to T1.
cells treated with 10 mM SB431542 for 3
hr (Figure 4C). These data agree with
the biological effects of both BMP4
that induces nuclear translocation of
SMAD1/5/8 and SB431542 that inhibits
nuclear translocation of SMAD2/3. Simi-
lar results were obtained with H9 cells
treated with BMP4 or SB431542 in the
presence of 10 mg/ml cycloheximide,
a protein synthesis inhibitor (Figure 4D),
suggesting direct binding of the SMADs
to the NANOG promoter.
FGF, TGFb, and BMP Signaling
Regulate NANOG Promoter Activity
By constructing luciferase reporter vec-
tors driven by various regions of the
NANOG promoter, we first confirmed
the essential role of the proximal region
(Figure S6) as previously reported (Kur-
oda et al., 2005). We used the reporter
vector driven by this region (pNANOG-
Luc) to test the effect of various signals
on NANOG promoter activity in the hu-
man ESC line H9. The reporter activity
was reduced by 10 mM SB431542 or by
TGFb1 withdrawal from T1 (T1[]TGFb1)
and greatly enhanced by the addition of Activin (Figure 5A). Inter-
estingly, either BMP4 addition to T1 or bFGF withdrawal from T1
alone did not reduce reporter activity, but both of these treat-
ments did augment the decline of the activity caused by
TGFb1 withdrawal or inhibition (Figure 5A). These data suggest
that TGFb/Activin plays a central role in sustaining NANOG pro-
moter activity in undifferentiated human ESCs. Overexpression
ofNANOG sustainedOCT4 expression in H9 cells in the absence
of FGF and TGFb signaling (Figure 6). These data indicate that
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ESC by sustaining NANOG expression.
Putative SBE Sites in the NANOG Proximal Promoter
Are Required for Its Activity
Wemutated each of the putative SBE sites to generate a mutant
reporter vector pNANOG(mSBEs)-Luc (Figure 3A) and tested the
effect of these mutations on the NANOG promoter activity in H9
cells. Compared to human ESCs transfected with the wild-type
reporter vector, cells transfected with pNANOG(mSBEs)-Luc
had dramatically reduced reporter activity, and SB431542 failed
to cause further reduction (Figure 5B). Similar reduction of the
reporter activity was seen with the vectors with mutated
Octamer elements and Sox elements in the NANOG promoter,
pNANOG(mOCT)-Luc and pNANOG(mSOX)-Luc, respectively
(Figure 4B), consistent with a previous report (Kuroda et al.,
2005). To set up a negative control (NC) for the above binding
site-specific mutations, we generated a vector named pNA-
NOG(NC)-Luc with two mutated sequences located down-
stream of the first SBE and upstream of the fourth SBE,
Figure 3. ChIP for SMADs Binding to the
NANOG Proximal Promoter
(A) Schematic representation of NANOG proximal
promoter region (not to scale) and mutagenesis
strategy (see Figure S4 for its complete sequence).
TSS: transcription start site; SBE: SMAD binding
element; NC: sequence mutated for negative con-
trol mutation; and red letters for mutated nucleo-
tide residues.
(B) ChIP assay for SMAD binding to the NANOG
proximal promoter. H1 cells were cultured in T1
medium, T1 + 10 mM SB431542 (T1[+]SB), or
T1 + 100 ng/ml BMP4 (T1[+]BMP4) for 24 hr. The
cells were harvested and processed for ChIP with
isogenic IgG, anti-SMAD1/5/8, or anti-SMAD2/3
antibodies. The enrichment of the precipitated
DNA by each of the antibodies versus the IgG
was analyzed by QPCR using primers flanking the
proximal promoter region. Results from two dupli-
cated experiments are shown as fold of DNA
enrichment. *p < 0.05, **p < 0.01 compared to T1.
respectively, in theNANOG proximal pro-
moter (Figure 3A). The reporter activity of
this vector was not significantly different
than that of the wild-type vector pNA-
NOG-Luc (Figure 5B). Taken together,
these data suggest that TGFb-responsive
SMADs may bind the putative SBEs and
sustain NANOG promoter activity and
that the effect of TGFb signaling on
NANOG promoter activity relies on the in-
tegrity of the putative SBEs and the Oc-
tamer/Sox elements in the promoter.
DISCUSSION
Recently developed feeder-free human
ESCmedia generally include an FGF fam-
ily member and an agonist of TGFb/Activin signaling (Amit et al.,
2004; Beattie et al., 2005; Levenstein et al., 2005; Li et al., 2005;
Lu et al., 2006; Ludwig et al., 2006b; Sato et al., 2004; Vallier
et al., 2005; Wang et al., 2005; Xu et al., 2005a, 2005b; Yao
et al., 2006). At the high concentrations of bFGF (100 ng/ml) in-
cluded in the defined media we used for the current studies, re-
moval of the exogenous TGFb has only very minor effects on cul-
ture performance, observable only when the cells are carefully
monitored over several passages (Ludwig et al., 2006b). How-
ever, inhibition of endogenous TGFb/Activin signaling in cells
grown in T1 resulted in a significant decline in the percentage of
cells expressingESCmarkers after only aweek of culture, indicat-
ing that autocrine TGFb/Activin signaling is important in these
specific culture conditions (Figure 2A). We also found that either
FGF or TGFb signaling repressed BMP signaling in human
ESCs in these conditions (Figure 1). However, although maintain-
ing BMP signaling below some threshold that could cause differ-
entiation is undoubtedly important, suppression of BMP signaling
alone is not sufficient to sustain prolonged culture of human ESCs
(Xu et al., 2005b), implying that FGF and TGFb play additional
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(A) DNA pull-down to verify probes for EMSA. A biotin-labeled probe of 80 bp was synthesized by PCR from the NANOG proximal promoter in the plasmid
pNANOG-Luc for a wild-type probe (WT) or from the mutated promoter in pNANOG(mSBEs)-Luc for a mutated probe (SBE mut). Only the WT probe was
able to pull down SMAD2/3 from the extract of H9 cells as verified by western blotting.
(B–D) EMSA on the nuclear extract (NE) from H9 cells untreated (B) or treated with 100 ng/ml BMP4 or 10 mMSB431542 for 3 hr in the absence (C) or presence (D)
of 10 mg/ml cycloheximide (Biomol, Plymouth Meeting, PA), a protein synthesis inhibitor. An unlabeled probe at 200-fold concentration of the labeled probe was
used as a competitor, anti-SMAD2/3 or anti-SMAD1/5/8 antibody for supershift and isogenic IgG as a control.roles. Both FGF and TGFb/Activin signaling are required to main-
tain a high percentage of OCT4+ cells in prolonged human ESC
culture in our current culture conditions, and FGF signaling is
also important for promoting proliferation (Figure 2A).
Among the core transcription factors involved in the control of
pluripotency,NANOG is downregulated themost in human ESCs
after TGFb/Activin signaling is blocked for 3 days (Table S1),
which led us to examine whether NANOG itself is a target of
SMAD signaling. The presence of repetitive SBEs in the NANOG
proximal promoter region suggested the potential involvement of
direct SMAD binding in the regulation of NANOG expression.
ChIP experiments using an antibody to SMAD2/3 documented
enrichment for the NANOG promoter region in undifferentiatedhuman ESCs. A gel shift assay suggested binding of SMAD2/3
or SMAD1/5/8 to the NANOG promoter DNA depending on acti-
vation of the TGFb or BMP signaling and integrity of the SBEs in
the promoter, and a luciferase NANOG reporter promoter assay
demonstrated an increase of activity correlated with conditions
where SMAD2/3 signaling is active. An antibody for SMAD1/5/8
demonstrated enrichment of the same NANOG promoter region
in BMP4-treated human ESCs. However, although addition of
BMP4 or withdrawal of bFGF reduced NANOG expression after
3 days, neither repressed the shorter term NANOG reporter as-
says unless TGFb/Activin signalingwas already absent. This sug-
gests that the TGFb signal dominates in determining the initial
level ofNANOG promoter activity and that FGF and BMP signals
Cell Stem Cell 3, 196–206, August 7, 2008 ª2008 Elsevier Inc. 201
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rect mechanisms. The fact that overexpression of NANOG by-
passed the need for both TGFb and FGF signaling to sustain hu-
man ESC self-renewal further suggests that these signaling
pathways act via regulation of NANOG expression.
It has been reported that Nanog can physically interact with
Smad1 in mouse ESCs, interfere with the recruitment of coactiva-
tors to active Smad transcriptional complexes, and repress the
expression of BMP-responsive genes (Suzuki et al., 2006). Our
data suggest that SMADs bind theNANOG promoter and regulate
NANOG expression, and both observations suggest a regulatory
loop between NANOG and SMADs. Figure 7 is a model for
SMAD-NANOG regulation that incorporates thesefindings.Further
studiesarenecessary to testwhetherSMADs formcomplexeswith
other transcription factors to bind target genes and confirm any
functional significance of a competition between SMAD1/5/8 and
SMAD2/3 in thebindingof thecofactorSMAD4.HowFGFsignaling
regulates the pluripotency genes also remains to be elucidated.
Figure 5. NANOG Proximal Promoter
Activity in Luciferase Reporter Assay
(A) Regulation of NANOG promoter reporter activ-
ity by FGF, TGFb, and BMP signaling. H9 cells
were transfected with pNANOG-Luc and a trace
amount of pGL4.70 (as an internal control) on
day 1. Treatments of the cells started on day 2
with T1 medium, T1 minus a specific signal stimu-
lator 100 ng/ml bFGF or 0.6 ng/ml TGFb1 (Tb), plus
10 ng/ml Activin, 100 ng/ml BMP4 (B4), or 10 mM
SB431542 (SB). After 24 hr of treatment, cells
were harvested for analysis of luciferase activity.
(B) Effect of SBE mutations on pNANOG-Luc
activity. H9 cells were transfected with wild-type
pNANOG-Luc (WT), pNANOG(mSBEs)-Luc
(mSBEs), pNANOG(mOCT)-Luc (mOCT),
pNANOG(mSOX)-Luc (mSOX), or pNANOG(NC)-
Luc (NC) on day 1 (all with pGL4.70); cultured in
T1 alone or T1 plus SB starting on day 2; and har-




TGFb1 (R&D Systems, Minneapolis, MN), bFGF
(Invitrogen, Carlsbad, CA), and LiCl (Sigma, St.
Louis, MO) were components in T1 medium (Lud-
wig et al., 2006b). These components were with-
drawn or added back to the medium to test the
gain or loss of function of TGFb, FGF, and WNT
pathways, respectively. In addition, 10 ng/ml Acti-
vin A or 10 mM SB431542 (Tocris, Ellisville, MO),
100 ng/ml BMP4 or 100 ng/ml Noggin (R&D Sys-
tems), and 100 ng/ml bFGF or 10 mM SU5402
(Pharmacia & Upjohn Co., Kalamazoo, MI) were
used to activate or inhibit TGFb, BMP, and FGF
signaling, respectively.
Medium and Cell Culture
Human ESC lines H1, H9, and H14 were used in
this study. Human ESCs were maintained on
plates coated with growth-factor-depleted matri-
gel (BD Biosciences, San Jose, CA) in either se-
rum-free, defined medium (Ludwig et al., 2006a)
or fibroblast-conditioned medium (Xu et al., 2001). Cell cultures in each of
these treatments were evaluated for OCT4 expression after 14 days (the
cells were split once after 7 days). Growth curves over two passages and
marker expression following 14 days of culture were also obtained as pre-
viously described (Ludwig et al., 2006b). A minimum of three replicates in
triplicate was performed. Statistical analysis was performed using ANOVA,
and percentage data was arcsine-transformed prior to analysis.
Luciferase Reporter Assay
A BMP-responsive firefly luciferase reporter plasmid, pID120-Luc (Lopez-
Rovira et al., 2002), was used to test BMP signaling levels in human ESCs
(Xu et al., 2005b). Luciferase reporter plasmids driven by various regions of
the NANOG promoter (Kuroda et al., 2005) were constructed by inserting
the following promoter regions into the promoterless pGL4.10 plasmid: the
longest (1942 to 24 in reference to the transcription start site), the proximal
(380 to 24), and the truncated (1942 to 380) (Promega, Madison, WI). Af-
ter confirmation of the essential role of the proximal promoter region (Kuroda
et al., 2005), the reporter plasmid driven by this region, named pNANOG-Luc,
was used throughout this study. To test the role of SMAD binding in regulation
of the NANOG promoter activity, we generated a mutated reporter vector,
pNANOG(mSBEs)-Luc, by mutating the four putative SBEs in the proximal
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(Stratagene). Mutations were also made on the Octamer and Sox elements
in the proximal promoter, generating two mutated reporter vectors,
pNANOG(mOCT)-Luc and pNANOG(mSOX)-Luc, respectively, as described
(Kuroda et al., 2005). Mutations of two nonspecific areas in the promoter re-
gion were made to generate another mutated reporter vector, pNANOG(NC)-
Luc, as a negative control (Figure 3A). All the mutations were confirmed by
sequencing.
The luciferase assay was performed by transfecting human ESCs on day 1
with each of the reporter vectors together with a trace amount (1/20 of the DNA
amount for the test vector) of pRL-tk or pGL4.70 plasmid (Promega) to express
Renilla luciferase as an internal control. FuGENE 6 (Roche Applied Science, In-
dianapolis, IN) was used for all the transfections. The cells were treated with
various media on day 2 and harvested on day 3 for luciferase assay. Both
the firefly and Renilla luciferase activities in the lysates were tested by using
the Dual-Luciferase Reporter Assay System (Promega) on a 3010 Luminome-
ter (BDBiosciences). The ratio between firefly luciferase activity and the Renilla
luciferase activity was obtained for each sample. Relative luciferase unit (RLU)
was calculated via normalization of each of the ration for all groups by the
average ratio for the control group.
Figure 6. NANOGOverexpression Bypasses the Need for Both TGFb
and FGF Signaling to Sustain Human ESC Self-Renewal
H1 cells transduced with lentiviral particles containing NANOG or EGFP and
selected by puromycin were split to plates with T1 medium. The next day,
the medium was replaced with T1, T1  TGFb1 + 10 mM SB431542
(T1[]TGFb1[+]SB), T1  bFGF + 10 mM SU5402 (T1[]bFGF[+]SU), or
T1()TGFb1(+)SB()bFGF(+)SU. After 5 day treatment with these media, the
cells were fixed and processed for immunostaining for OCT4 expression.
SU5402 has previously been shown to inhibit the level of phosphorylated
ERK in human ESCs (Kang et al., 2005).Flow Cytometry
Human ESCs cultured in various media were processed for flow cytometry
analysis to detect OCT4+ cells as described (Xu et al., 2002). Mouse anti-
human OCT4 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at
2 mg/ml and AlexaFluor 488-labeled rabbit anti-mouse IgG (Invitrogen) at
1:1000 dilution were used.
Immunoassay of HCG in Spent Culture Medium
Human ESCs cultured in conditioned medium were rinsed with DMEM/F12
basal medium and switched to T1 with or without various concentrations of
bFGF and 100 ng/ml BMP4 for 7 days with daily refreshment of the media.
The spent media were collected on day 7 and assayed for HCG as described
(Xu et al., 2002).
Reverse Transcription-QPCR
Total cellular RNA was extracted by Trizol Reagent (Invitrogen) and treated
with RQ1 RNase-free Dnase (Promega) according to the manufacturer’s
instructions. Total RNA was reverse-transcribed to generate cDNA using the
High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). The
cDNA pool was subjected to QPCR by using 2X TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems) on the AB 7300 Real Time PCR System (Applied
Biosystems). The following conditions were used in QPCR: 2 min at 50C, 10
min at 95C, and 40 cycles of 15 s at 95C and 1 min at 60C. TaqMan Gene
Expression Assays (Table S2) were used, and the b2M assay was tested as an
endogenous reference to calculate the relative expression levels of target
genes according to Applied Biosystems’ instructions.
ChIP-QPCR
Human ESCs were grown to a final count of about 13 108 cells for each reac-
tion. Cells were chemically crosslinked by the addition of one-tenth volume of
fresh 11% formaldehyde solution for 15 min at room temperature. Cells were
rinsed twice with 13 PBS and harvested using a silicon scraper and flash-fro-
zen in liquid nitrogen and stored at –80C prior to use. Upon thawing, the cells
were lysed using lysis buffer and sonicated to solubilize and shear crosslinked
DNA. We used a Sonicator 3000 (Misonix, Farmingdale, NY) and sonicated at
power 7 for 103 30 s pulses (90 s pause between pulses) at 4Cwhile samples
were immersed in an ice bath. The resulting whole-cell extract was incubated
at room temperature for 1 hr with 100 ml Protein G magnetic beads that had
been preincubated with the appropriate antibodies against SMAD2/3 (Cell Sig-
naling Technology, Danvers, MA) or SMAD1/5/8 (Santa Cruz Biotechnology) or
an isogenic immunoglobin at 4C overnight. Beads were washed five times
with RIPA buffer and one time with TE containing 50 mM sodium chloride.
Bound complexes were eluted from the beads by heating at 65C with occa-
sional vortexing, and crosslinking was reversed by overnight incubation at
Figure 7. Model of SMAD Regulation of NANOG Transcription in
Human ESCs
Arrows represent induction, and hammer-ended lines represent inhibition.
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treated for crosslink reversal. Immunoprecipitated DNA and whole-cell extract
DNA were then purified by treatment with RNaseA, proteinase K, and multiple
phenol:chloroform:isoamyl alcohol extractions. Purified DNA was used as
template for QPCR to amplify the proximal promoter of NANOG with the for-
ward primer sequence 50-CTT CAG GTT CTG TTG CTC GGT TTT C and re-
verse primer sequence 50-TCC CGT CTA CCA GTC TCA CCA. The PCR prod-
uct size was 101 bp. The 2X iQ SYBR Green Supermix was used for QPCR on
the AB 7300 Real Time PCR System. The following PCR conditions were used:
10 min at 95C and 40 cycles of 30 s at 95C and 1 min at 60C.
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared from human ESC line using NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Pierce, Rockford, IL) based on the
manufacturer’s instructions and stored at 80C. A DNA probe of 80 bp
was synthesized by PCR from the proximal NANOG promoter in the pNA-
NOG-Luc plasmid using a forward primer (labeled with biotin at the 50
end) 50-CCC ACC TAG TCT GGG TTA CTC TGC-30 and reverse primer
50- TCT CAG TTA ATC CCG TCT ACC AGT C-30. An unlabeled wild-type
competitor was synthesized the same way except that an unlabeled forward
primer was used. A probe mutated at the four SBEs was synthesized by
PCR from the plasmid pNANOG(mSBEs)-Luc. The DNA probes were gel
purified and used in the electrophoretic mobility shift assay (EMSA) and
DNA pull-down assays.
The EMSA was performed by using the LightShift Chemiluminescent EMSA
Kit (Pierce) based on the manufacturer’s instructions. One microgram of the
nuclear extract and 1 ng of the biotin-labeled probe were mixed in the
EMSA Binding Buffer (Pierce). Where specified, 200 ng unlabeled competitor
1:10 dilution of the anti-SMAD2/3 or anti-SMAD1/5/8 antibody or isogenic IgG
was added and incubated on ice for 1 hr prior to the addition of the labeled
probe. The binding reactions were incubated for 20 min at room temperature
and resolved on a prerun 6% PAGE gel in 0.5 M Tris-borate-EDTA for 1.5 hr at
80 V. The resolved reactions on the gel were transferred to a Zeta Probe mem-
brane (BioRad, Hercules, CA). The membrane was air-dried, UV-crosslinked,
blocked in the Blocking Solution, and then incubated with streptavidin conju-
gated with horseradish peroxidase followed by substrates of the peroxidase
(all from Pierce). Locations of the biotin-labeled probe on the membrane
were visualized and recorded by FujiImager (Japan).
DNA Pull-Down and Western Blotting
Human ESCs cultured in 6-well plates were harvested and lysed in the DP
buffer composed of 50 mM HEPES (pH 7.4), 150 mM sodium chloride, 15 mM
sodium fluoride, 2 mM ethylene diamine tetraacetic acid, 1 mM ethylene
glycol tetraacetic acid, 10% glycerol, 1% Triton X-100, 20mM b-glycerophos-
phate, 1mMsodium pyrophosphate, 0.5%bovine serum albumin, and a cock-
tail of freshly added protease inhibitors including 10 mg/ml aprtinin, 10 mg/ml
leupeptin, and 1 mM orthovanadate. The protein concentration of the cell
lysate was determined. Three hundred microliters of streptavidin-agarose
beads (Pierce) were pelleted, washed, and preabsorbed with 500 ml of
1 mg/ml BSA, 50 mg Poly(dI:dC), and 50 mg sheared salmon sperm DNA for
30 min at room temperature for preblocking. The beads were washed five
times and resuspended in 300 ml of the DP buffer. One microgram of the
biotin-labeled DNA probe (wild-type or mutated) (see above) was incubated
with 300 mg of the cellular proteins in the EMSA Binding Buffer (Pierce) for
20 min at room temperature. Thirty micrograms of the preblocked streptavi-
din-agarose beads were added to the probe-lysate reaction and incubated
at 4C overnight for biotin-mediated binding. The bound beads were washed
five times with the DP buffer and resuspended in 20 ml of Alaemli Buffer (Bio-
Rad). The suspension was boiled for 5 min. Fifteen microliters of the superna-
tant were loaded onto a SDS gel for western blotting to detect SMAD2/3 with
the anti-SMAD2/3 antibody.
Lentiviral Transduction of NANOG to Human ESCs
The cDNA for the open reading frame of human NANOG (accession:
NM_024865) was obtained by PCR amplification from a cDNA pool of human
ESCs. A cassette containing the NANOG cDNA, the internal ribosomal entry
site, and the puromycin-resistant gene was cloned into a lentiviral vector mod-
ified from those, as previously described by us (Ma et al., 2003). The 293FT cell
204 Cell Stem Cell 3, 196–206, August 7, 2008 ª2008 Elsevier Inc.line (Invitrogen) was used to produce transgene-expressing lentivirus. For
packaging, 293FT cells were cotransfected with the NANOG-expressing lenti-
viral vector and two helper plasmids, pMD.G and psPAX2, with Superfect
Transfection Reagent (QIAGEN, Valencia, CA). Three days posttransfection,
the viral particles were harvested and concentrated from the supernatant by
ultracentrifugation. The titer obtained generally ranged from 107 to 108 viral
particles/ml.
For NANOG transduction, the human ESCs that had been partially trypsi-
nized were plated at 2 3 105 cells/well in fibroblast-conditioned medium on
matrigel-coated plates. The next day, the lentiviral particles containing
NANOG or an enhanced green fluorescent protein (EGFP, as a negative con-
trol) were added to the cell cultures at a multiplicity of infection of20 per well
in the presence of polybrene at 6 mg/ml (Sigma). Following overnight incuba-
tion, the lentivirus-containing medium was replaced with fresh conditioned
medium. The transduced cells were propagated as nontransduced cells,
and selection with puromycin at 0.5 mg/ml started 5 days posttransduction.
The expression of the NANOG transgene or EGFP expression in human
ESCs following selection was confirmed by RT-PCR (data not shown). The
cells were then split to plates with T1 medium. The next day, the cells were
treated with various media to inhibit either TGFb or FGF signaling or both. After
5 day treatment, the cells were fixed and processed for immunostaining for
OCT4 expression.
Immunohistochemistry
Cells were immunostained as described (Xu et al., 2005b). Rabbit anti-human
OCT4 antibody (Santa Cruz Biotechnology) at 1:400 and Alexa Fluor 594-
labeled anti-rabbit IgG secondary antibodies (Molecular Probes) at 1:1000
dilution were used to detect OCT4 in the cells. For Figure S2B, the anti-
human SMAD2/3 antibody at 0.2 mg/ml and Alexa Fluor 488-labeled anti-
mouse IgG secondary antibodies (Molecular Probes) at 1:1000 dilution
were used to detect SMAD2/3 in the cells. DAPI-coated slides were used
to stain the nuclei of the cells.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, two
tables, and six figures and can be found with this article online at http://
www.cellstemcell.com/cgi/content/full/3/2/196/DC1/.
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